Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis

on behalf of Deutsche Studiengruppe Multiples Myelom

doi:10.1038/s41375-019-0537-2

Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis

on behalf of Deutsche Studiengruppe Multiples Myelom

University Medical Center Hamburg-Eppendorf
St. Marien-Hospital Hamm
Saarland University Medical Center
University Heart Center
Municipal Hospital
Klinikum Nord
Klinium Stuttgart
Diakonissenkrankenhaus
University of Würzburg
University of Freiburg
University Medical Center Ulm and Center of Excellence 'Metabolic Disorders'
University of Tübingen
University of Regensburg
Klinikum der Universität Regensburg und Medizinische Fakultät
Universität Oldenburg
Klinikum
Hannover Medical School
Medical School
Robert-Bosch-Hospital
City Hospital Munich-Schwabing
Innenstadt Klinikum
Otto-von-Guericke University
Division of Hematology and Medical Oncology
Charité – Universitätsmedizin Berlin
Red Cross Hospital
Ludwig-Maximilians-Universität München
University Medical Center
Klinikum Bremen-Mitte
University of Rostock
Rostock University Medical Center
University of Münster
Universitätsklinikum Münster
University Medicine Greifswald
University Hospital
University Hospital
University Medical Center
Dr. Horst-Schmidt-Klinik
Helios Hospital
Karolinska Institutet
Ernst von Bergmann Hospital
E.v.Bergmann Klinikum
Bolzano Municipal Hospital
Central Hospital
University Hospital Schleswig-Holstein
Universitätsklinikum Tübingen
Helios Klinikum
St. Johannes Hospital
Universitätsklinikum Carl Gustav Carus Dresden
Universitätsklinikum Erlangen
Klinikum der J. W. Goethe-Universität

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

This phase 3 trial compared tandem autologous stem cell transplantation (autoSCT) versus autoSCT followed by reduced-intensity conditioning allogeneic stem cell transplantation (auto/alloSCT) in patients with newly diagnosed multiple myeloma (MM) with deletion of (del) chromosome 13q (del13q). The availability/absence of a human leukocyte antigen-matched-related or matched-unrelated donor (MUD) determined the nature of the second SCT. The primary endpoint was progression-free survival (PFS) in the intention-to-treat population (n = 199). Auto/alloSCT was performed in 126 patients; 74 received MUD allografts. After 91 months median follow-up, median PFS with auto/allo versus tandem autoSCT was 34.5 versus 21.8 months (P = 0.003; adjusted hazard ratio 0.55, 95% confidence interval 0.36–0.84). Median overall survival (OS) was 70.2 versus 71.8 months (P = 0.856). Two-year non-relapse mortality with auto/allo versus tandem autoSCT was 14.3% versus 4.1% (P = 0.008). In patients harboring both del13q and del17p, median PFS and OS were 37.5 and 61.5 months with auto/allo (n = 19) versus 6.1 and 23.4 months with tandem autoSCT (n = 6) (P = 0.0002 and 0.032). Our findings suggest that auto/alloSCT significantly extends PFS versus tandem autoSCT in del13q MM, and indicate some survival benefit for first-line alloSCT in high-risk MM.

Original language	English
Pages (from-to)	2710-2719
Number of pages	10
Journal	Leukemia
Volume	33
Issue number	11
DOIs	https://doi.org/10.1038/s41375-019-0537-2
State	Published - 1 Nov 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41375-019-0537-2

Cite this

@article{ab44d2ab712c44e88fc9f305826e2459,

title = "Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis",

abstract = "This phase 3 trial compared tandem autologous stem cell transplantation (autoSCT) versus autoSCT followed by reduced-intensity conditioning allogeneic stem cell transplantation (auto/alloSCT) in patients with newly diagnosed multiple myeloma (MM) with deletion of (del) chromosome 13q (del13q). The availability/absence of a human leukocyte antigen-matched-related or matched-unrelated donor (MUD) determined the nature of the second SCT. The primary endpoint was progression-free survival (PFS) in the intention-to-treat population (n = 199). Auto/alloSCT was performed in 126 patients; 74 received MUD allografts. After 91 months median follow-up, median PFS with auto/allo versus tandem autoSCT was 34.5 versus 21.8 months (P = 0.003; adjusted hazard ratio 0.55, 95\% confidence interval 0.36–0.84). Median overall survival (OS) was 70.2 versus 71.8 months (P = 0.856). Two-year non-relapse mortality with auto/allo versus tandem autoSCT was 14.3\% versus 4.1\% (P = 0.008). In patients harboring both del13q and del17p, median PFS and OS were 37.5 and 61.5 months with auto/allo (n = 19) versus 6.1 and 23.4 months with tandem autoSCT (n = 6) (P = 0.0002 and 0.032). Our findings suggest that auto/alloSCT significantly extends PFS versus tandem autoSCT in del13q MM, and indicate some survival benefit for first-line alloSCT in high-risk MM.",

author = "\{on behalf of Deutsche Studiengruppe Multiples Myelom\} and Stefan Knop and Monika Engelhardt and Peter Liebisch and Christoph Meisner and Ernst Holler and Bernd Metzner and Dietrich Peest and Martin Kaufmann and Donald Bunjes and Christian Straka and Thomas Fischer and Orhan Sezer and Marcus Hentrich and Helmut Ostermann and Florian Bassermann and Georg Hess and Bernd Hertenstein and Mathias Freund and Martin Kropff and Schmidt, \{Christian A.\} and Wolf, \{Hans Heinrich\} and Wolfram Jung and Norbert Frickhofen and Stephan Mielke and Bargou, \{Ralf C.\} and Georg Maschmeyer and Mirija Svaldi and Langer, \{Christian H.\} and Martin Gramatzki and Holger Hebart and Lothar Kanz and Hermann Einsele and B. D{\"o}rken and C. Gerecke and S. Fuhrmann and Ludwig, \{W. D.\} and M. Bormann and R. Meyer and R. Naumann and U. Platzbecker and Ch R{\"o}llig and W. R{\"o}sler and Metzler, \{I. von\} and H. Martin and J. Finke and L. Tr{\"u}mper and G. D{\"o}lken and L. M{\"u}ller and K. Ligeti and C. Peschel",

note = "Publisher Copyright: {\textcopyright} 2019, The Author(s), under exclusive licence to Springer Nature Limited.",

year = "2019",

month = nov,

day = "1",

doi = "10.1038/s41375-019-0537-2",

language = "English",

volume = "33",

pages = "2710--2719",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "11",

}

TY - JOUR

T1 - Allogeneic transplantation in multiple myeloma

T2 - long-term follow-up and cytogenetic subgroup analysis

AU - on behalf of Deutsche Studiengruppe Multiples Myelom

AU - Knop, Stefan

AU - Engelhardt, Monika

AU - Liebisch, Peter

AU - Meisner, Christoph

AU - Holler, Ernst

AU - Metzner, Bernd

AU - Peest, Dietrich

AU - Kaufmann, Martin

AU - Bunjes, Donald

AU - Straka, Christian

AU - Fischer, Thomas

AU - Sezer, Orhan

AU - Hentrich, Marcus

AU - Ostermann, Helmut

AU - Bassermann, Florian

AU - Hess, Georg

AU - Hertenstein, Bernd

AU - Freund, Mathias

AU - Kropff, Martin

AU - Schmidt, Christian A.

AU - Wolf, Hans Heinrich

AU - Jung, Wolfram

AU - Frickhofen, Norbert

AU - Mielke, Stephan

AU - Bargou, Ralf C.

AU - Maschmeyer, Georg

AU - Svaldi, Mirija

AU - Langer, Christian H.

AU - Gramatzki, Martin

AU - Hebart, Holger

AU - Kanz, Lothar

AU - Einsele, Hermann

AU - Dörken, B.

AU - Gerecke, C.

AU - Fuhrmann, S.

AU - Ludwig, W. D.

AU - Bormann, M.

AU - Meyer, R.

AU - Naumann, R.

AU - Platzbecker, U.

AU - Röllig, Ch

AU - Rösler, W.

AU - Metzler, I. von

AU - Martin, H.

AU - Finke, J.

AU - Trümper, L.

AU - Dölken, G.

AU - Müller, L.

AU - Ligeti, K.

AU - Peschel, C.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - This phase 3 trial compared tandem autologous stem cell transplantation (autoSCT) versus autoSCT followed by reduced-intensity conditioning allogeneic stem cell transplantation (auto/alloSCT) in patients with newly diagnosed multiple myeloma (MM) with deletion of (del) chromosome 13q (del13q). The availability/absence of a human leukocyte antigen-matched-related or matched-unrelated donor (MUD) determined the nature of the second SCT. The primary endpoint was progression-free survival (PFS) in the intention-to-treat population (n = 199). Auto/alloSCT was performed in 126 patients; 74 received MUD allografts. After 91 months median follow-up, median PFS with auto/allo versus tandem autoSCT was 34.5 versus 21.8 months (P = 0.003; adjusted hazard ratio 0.55, 95% confidence interval 0.36–0.84). Median overall survival (OS) was 70.2 versus 71.8 months (P = 0.856). Two-year non-relapse mortality with auto/allo versus tandem autoSCT was 14.3% versus 4.1% (P = 0.008). In patients harboring both del13q and del17p, median PFS and OS were 37.5 and 61.5 months with auto/allo (n = 19) versus 6.1 and 23.4 months with tandem autoSCT (n = 6) (P = 0.0002 and 0.032). Our findings suggest that auto/alloSCT significantly extends PFS versus tandem autoSCT in del13q MM, and indicate some survival benefit for first-line alloSCT in high-risk MM.

AB - This phase 3 trial compared tandem autologous stem cell transplantation (autoSCT) versus autoSCT followed by reduced-intensity conditioning allogeneic stem cell transplantation (auto/alloSCT) in patients with newly diagnosed multiple myeloma (MM) with deletion of (del) chromosome 13q (del13q). The availability/absence of a human leukocyte antigen-matched-related or matched-unrelated donor (MUD) determined the nature of the second SCT. The primary endpoint was progression-free survival (PFS) in the intention-to-treat population (n = 199). Auto/alloSCT was performed in 126 patients; 74 received MUD allografts. After 91 months median follow-up, median PFS with auto/allo versus tandem autoSCT was 34.5 versus 21.8 months (P = 0.003; adjusted hazard ratio 0.55, 95% confidence interval 0.36–0.84). Median overall survival (OS) was 70.2 versus 71.8 months (P = 0.856). Two-year non-relapse mortality with auto/allo versus tandem autoSCT was 14.3% versus 4.1% (P = 0.008). In patients harboring both del13q and del17p, median PFS and OS were 37.5 and 61.5 months with auto/allo (n = 19) versus 6.1 and 23.4 months with tandem autoSCT (n = 6) (P = 0.0002 and 0.032). Our findings suggest that auto/alloSCT significantly extends PFS versus tandem autoSCT in del13q MM, and indicate some survival benefit for first-line alloSCT in high-risk MM.

UR - https://www.scopus.com/pages/publications/85071942264

U2 - 10.1038/s41375-019-0537-2

DO - 10.1038/s41375-019-0537-2

M3 - Article

C2 - 31462732

AN - SCOPUS:85071942264

SN - 0887-6924

VL - 33

SP - 2710

EP - 2719

JO - Leukemia

JF - Leukemia

IS - 11

ER -

Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this